A Study of LY2409021 in Healthy Participants

A Single Dose Pharmacokinetic Study of LY2409021 Tablet Administered in Healthy Subjects

The study involves a single dose of LY2409021 taken by mouth. The purpose of this study is to determine how much LY2409021 enters the bloodstream and how long the body takes to get rid of the drug after the dose. This study will last approximately 28 days, not including screening. Screening can occur within 30 days prior to the start of the study.

Inclusion Criteria:

• Healthy males or females as determined by medical history
• Satisfactory clinical laboratory and physical examination tests
• Have a body mass index (BMI) of 18 to 32.0 kilograms per meter squared (kg/m^2)

Exclusion Criteria:

- Abnormal electrocardiograms (ECGs)